Derivatives of cephalosporin for treating cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 3, 2020
Grant Date -
May 4, 2017
app pub date -
Apr 2, 2015
filing date -
Apr 3, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2015 Application Filing Year
- A61K Class
- 16157 Applications Filed
- 11882 Patents Issued To-Date
- 73.55 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 5 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | May 3, 2028 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | May 3, 2032 |
